Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Speedus (CE) Charts. Click Here for more Speedus (CE) Charts.](/p.php?pid=staticchart&s=NO%5ESPDE&p=8&t=15)
FDA Clears Zargis' Pioneering Medical Device
First Computer-Aided Device to Assist in the Detection of Heart Murmurs
PRINCETON, N.J., June 1 /PRNewswire/ -- Zargis Medical Corp., a majority-
owned subsidiary of Speedus Corp. (NASDAQ:SPDE), announced today it has
received U.S. Food and Drug Administration (FDA) clearance to market Zargis
Acoustic Cardioscan (Cardioscan), the first and only computer-aided medical
device to support physicians in analyzing heart sounds for the identification
of suspected murmurs, a potential sign of heart disease.
"Zargis is the only company that has been able to achieve this significant
milestone, which demonstrates our outstanding technical expertise and core
competency in this clinically important field," said Zargis President and Chief
Executive Officer, Shahram Hejazi, Ph.D.
"We are extremely pleased by this FDA clearance which helps pave the way for
future Zargis products. It is our hope that Cardioscan, the first product of
its kind, will become the new standard of care," said Silvano Dall'Asta, Zargis
Director and CFO of Zargis partner, Siemens Corporate Research, Inc.
About Cardioscan
Cardioscan is easy to use, non-invasive, portable, and takes just minutes to
perform. Developed by biomedical scientists from Siemens and Zargis over the
past seven years, Cardioscan acquires, processes and analyzes heart sounds,
then provides easily interpretable graphical and textual results to physicians.
Using Cardioscan to identify suspected murmurs through the assessment of
patients' heart sounds, physicians will have an added tool available to them in
identifying the presence of murmurs that will assist them in their
determination of whether further testing or specialized attention from a
cardiologist is warranted. In addition, Cardioscan will provide an electronic
and printable record of a patient's heart sounds, giving the physician a
baseline, and an additional means by which to detect and track changes over
time. Dr. Alvin J. Chin, MD, Professor of Pediatrics, University of
Pennsylvania School of Medicine and Zargis advisor said, "I was most impressed
with the Cardioscan prototype. It is simple, clean, elegant and will be a
valuable decision support tool for most physicians".
Cardioscan will initially be launched to a select group of physicians, teaching
hospitals and other health care professionals.
About the FDA Submission
A clinical study utilizing data obtained from leading national medical centers
including Children's Hospital of Philadelphia, Texas Heart Institute in Houston
and St. Francis Medical Center in Roslyn, N.Y. demonstrated the detection of
heart murmurs by Cardioscan with a sensitivity of 91.8% and a specificity of
68.0%. A study published by the American Medical Association(1) reported only
20% correctness among 450 internal medicine and family practice physician
residents in identifying 12 basic heart sounds and murmurs. Listening to the
heart with a stethoscope remains the most widely used method for the detection
of heart murmurs. Cardioscan also achieved 91% sensitivity and at least 92%
positive predictivity in the identification of S1 and S2, two dominant heart
sounds in each heart beat that are important for the identification of heart
murmurs. S1 is commonly referred to as the "lub" sound and S2 the "dub" sound.
About Heart Murmurs
Certain types of valvular and congenital heart disease are manifested by heart
murmurs and proper interpretation is essential for accurate diagnosis and
disease management. According to published studies, it is estimated that
approximately 30% of the adult population, and up to 80% of children are
affected by heart murmurs. Although only a small percentage of these murmurs
result from heart disease, and even fewer are life threatening, the American
Heart Association states that valvular heart disease affects more than 20
million people in the United States, while another 1 million Americans are
living with congenital cardiovascular defects. Moreover, according to the same
report, mortality for diseases of the heart that may be related to a murmur is
in excess of 49,000 per year. "Cardioscan can be an important tool for aiding
in the early identification and assessment of sounds that could signify heart
disease," said Dr. Hejazi. "This device could provide doctors with a much
needed tool to help them provide better care to their patients while optimizing
the healthcare process."
Zargis Growth Opportunities
Given the limitations of the human auditory system, Zargis believes that one
day computer-assisted detection of sounds will be utilized in every patient
encounter where a stethoscope is used. Zargis and its partners are committed
to supporting continued research and development to commercialize medical
products that facilitate the detection, monitoring and diagnosis of diseases
which are manifested by cardiac and respiratory sounds.
Zargis Medical Corp. was formed in January 2001 when Siemens Corporate Research
Inc., a subsidiary of Siemens AG (NYSE:SI), and Speedus Corp. (NASDAQ:SPDE)
co-invested in Zargis to further develop and commercially market an advanced
acoustic technology for detecting heart murmurs and other abnormalities. Based
in Princeton, New Jersey, Zargis is developing advanced diagnostic decision
support products and services for primary care physicians, cardiologists and
other healthcare professionals.
For additional information about Zargis Medical Corp., contact Shahram Hejazi,
609.734.6530, , or visit their website at http://www.zargis.com/.
For additional information on Speedus Corp., contact John Kallassy,
718.567.4358, , or visit their website at http://www.speedus.com/.
For additional information on Siemens Corporate Research, visit their website
at http://www.scr.siemens.com/.
(1) "Study: Most new doctors can't use stethoscope; Only 20 percent 'hear'
common heart problems," CNNinteractive, 1997.
http://www.cnn.com/HEALTH/9709/02/nfm.heart.sounds/
Statements contained herein that are not historical facts, including but not
limited to statements about the Company's product, corporate identity and
focus, may be forward-looking statements that are subject to a variety of risks
and uncertainties. There are a number of important factors that could cause
actual results to differ materially from those expressed in any forward-
looking statements made by the Company, including, but not limited to, the
continuing development of the Company's sales, marketing and support efforts.
DATASOURCE: Zargis Medical Corp.
CONTACT: Shahram Hejazi, +1-609-734-6530, , for Zargis
Medical Corp.; or John Kallassy, +1-718-567-4358, , for
Speedus Corp
Web site: http://www.speedus.com/
http://www.scr.siemens.com/
http://www.zargis.com/